A student-run resource for reliable reports on the latest law and technology news

Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott 

Written By: Hyeongsu Park - Edited By: Kendra Albert

The market for therapeutic antibodies is projected to reach hundreds of billion dollars within the next several years. In Centocor v. Abbott, the Court of Appeals for the Federal Circuit (“Federal Circuit”) held that a patentee cannot claim an antibody unless the specification describes it, even if he/she fully characterizes the antigen, and the court vacated a $1.67 billion jury verdict, the largest patent infringement award in U.S. history.

Read More...

Posted On Mar - 13 - 2014 Comments Off READ FULL POST
  • RSS
  • Facebook
  • Twitter
  • GooglePlay
Unknown

Flash Digest: News i

By Anne Woodworth UK Court Allows Safari Users to Sue Google ...

e222580_includeB

Federal Circuit Reje

By Paulius Jurcys – Yaping Zhang Order: Halo Electronics, Inc. v. ...

600px-NetNeutrality_logo.svg_

The FCC’s Net Neut

By Shuli Wang - Edited by Yaping Zhang THE FCC 15-24 ...

13399-surveillance_news

White House releases

By Lan Du – Edited by Katherine Kwong Administration Discussion Draft: ...

Unknown

Federal Circuit Flas

By Patrick Gallagher Federal Circuit Affirms Denial of AT&T Motion to ...